Nifedipine Tablet, Extended Release
Product Images NDC 0615-8549

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 0615-8549). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

01 (Nifedipine 8549 1)

01 (Nifedipine   8549 1)
Chemical structure of nifedipine showing its molecular configuration with functional groups including nitro and ester moieties attached to a dihydropyridine ring.*
FDA Label Image

02 (Nifedipine 8549 2)

02 (Nifedipine   8549 2)
A table comparing the incidence percentages of adverse effects between Nifedipine extended-release tablets (N=707) and placebo (N=266). Effects listed include headache, fatigue, dizziness, constipation, and nausea, with higher percentages reported in the Nifedipine group for most categories.*
FDA Label Image

03 (Nifedipine 8549 3)

03 (Nifedipine   8549 3)
A data table listing adverse effects and their incidence percentages comparing Nifedipine capsules (N=226) with placebo (N=235). Adverse effects include dizziness, flushing, headache, weakness, nausea, muscle cramps, peripheral edema, nervousness, palpitations, dyspnea, and nasal congestion, with respective percentages for each group.*
FDA Label Image

04 (Nifedipine 8549 4)

FDA Label Image

Principal Display Panel (Nifedipine 8549 5)

Principal Display Panel (Nifedipine   8549 5)
Nifedipine Extended-Release Tablets USP 60 mg carton label for oral tablet form. The label shows NCS HealthCare of KY, LLC dba Vangard Labs as the labeler, with a quantity of 30 tablets per package. It includes storage instructions, dosage form details, and multiple barcode sections. The label also specifies the tablet is extended-release and states tablets should not be bitten or divided.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.